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          Parkinson’s Disease (PD) is the most common movement disorder and second most common 
neurodegenerative disease. The principal hallmark of  the pathology is represented by a loss of  mesence-
phalic Dopaminergic neurons (mesDA) that reside in the Substantia Nigra pars compacta (SNpc). Another 
feature of  the disease is represented by formation of  abnormal protein aggregates, known as Lewy Bod-
ies (LBs), mainly composed by the a-synuclein protein. The etiology of  mesDA death is still unknown, 
however LBs formation could represent one of  the factor contributing to neuronal mesDA death and PD 
progression.
Cell Replacement Therapy for PD aims at restoring the function of  the dopaminergic neurons through 
the transplantation of  the lost cells in the brain. Recently, cell sources derived from stem cells such as human 
embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSC) have been investigated 
and implicated in clinical trials for PD. Another route for generating neurons is represented by the direct 
reprogramming of  terminally differentiated cells. With the overexpression of  specific transcription factors 
(TFs) and/or micro RNA (miRNA) is possible to target somatic cells in vitro or resident brain cells in vivo 
for reprogramming into mesDA neurons. 
The overall aim of  my thesis has been to study functional and transcriptional profile of  newly gener-
ated mesDA neurons in vitro and in vivo for cell-based therapies of  PD. Indeed the transplantation outcome 
depends on the ability to generate mesDA neurons that are as similar as possible to the endogenous DA 
neurons. However, our knowledge of  human DA neurons is limited by the inaccessibility of  developing 
and adult brain tissues. In the first part of  my thesis I focused on studying the properties of  directly re-
programmed cells to determine their phenotypic and functional profile. In the second part of  this thesis, I 
performed an extensive molecular, transcriptional and functional analysis of  human fetal mesDA neurons 
to increase our understanding of  DA neurons. Lastly, I focused on establishing a stem cell derived organoid 
system that allowed for the generation of  authentic human DA neurons.
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5To my family
“The mind is not a vessel to be filled 
but a fire to be kindled.”
Plutarch
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ABSTRACT
Parkinson’s Disease (PD) is the most common movement disorder and second most common 
neurodegenerative disease. The principal hallmark of  the pathology is represented by a loss of  mesen-
cephalic Dopaminergic neurons (mesDA) that reside in the Substantia Nigra pars compacta (SNpc). 
Another feature of  the disease is represented by formation of  abnormal protein aggregates, known 
as Lewy Bodies (LBs), mainly composed by the a-synuclein protein. The etiology of  mesDA death 
is still unknown, however LBs formation could represent one of  the factor contributing to neuronal 
mesDA death and PD progression.
Cell Replacement Therapy for PD aims at restoring the function of  the dopaminergic neurons 
through the transplantation of  the lost cells in the brain. Recently, cell sources derived from stem 
cells such as human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSC) 
have been investigated and implicated in clinical trials for PD. Another route for generating neurons 
is represented by the direct reprogramming of  terminally differentiated cells. With the overexpression 
of  specific transcription factors (TFs) and/or micro RNA (miRNA) is possible to target somatic cells 
in vitro or resident brain cells in vivo for reprogramming into mesDA neurons. 
The overall aim of  my thesis has been to study functional and transcriptional profile of  newly 
generated mesDA neurons in vitro and in vivo for cell-based therapies of  PD. Indeed the transplanta-
tion outcome depends on the ability to generate mesDA neurons that are as similar as possible to the 
endogenous DA neurons. However, our knowledge of  human DA neurons is limited by the inacces-
sibility of  developing and adult brain tissues. In the first part of  my thesis I focused on studying the 
properties of  directly reprogrammed cells to determine their phenotypic and functional profile. In the 
second part of  this thesis, I performed an extensive molecular, transcriptional and functional analysis 
of  human fetal mesDA neurons to increase our understanding of  DA neurons. Lastly, I focused on 
establishing a stem cell derived organoid system that allowed for the generation of  authentic human 
DA neurons.
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LAY SUMMARY
Parkinson’s Disease (PD) is the most common movement disorder and second most common 
neurodegenerative disorder after Alzheimer Disease. The symptoms experienced by patients are 
mainly related to motor impairment however some patients experience neuropsychiatric disturbances, 
autonomic and sensory dysfunctions and sleep problems. The principal hallmark of  the pathology is 
represented by a loss of  neurons in the brain that in healthy conditions modulate motor output and 
control by releasing the neurotransmitter Dopamine (DA). 
Cell Replacement Therapy aims at restoring the function of  these neurons through the transplan-
tation of  new cells in the brain of  PD patients. Notably, stem cells have the capability of  generating 
neurons when specific protocols are applied for their differentiation in the laboratory. Clinical trials 
for PD are nowadays taking place using these cells, however, stem cells have the main feature of  being 
highly proliferative in an undifferentiated state giving rise to concerns for tumor formation in their 
application for cell transplantation approaches. Other venues for generating neurons are currently 
under investigation such as the direct conversion of  skin fibroblasts so called induced neurons (iNs) 
or resident brain cells into the desired neurons. This allows for the generation of  neurons without 
passing through a proliferative step, potentially decreasing the risk of  tumor formation. 
An important aspect to consider when generating neurons for transplantations, is how closely 
these new cells resemble the authentic DA neurons residing in the human brain. However, our knowl-
edge of  human dopaminergic neurons is limited by the inaccessibility of  the brain tissue during and 
after development.
In the first part of  my thesis I focused on determining properties of  gene and protein expression 
together with functional aspects of  directly reprogrammed cells starting from human skin cells or 
resident mouse brain cells. In the second part of  the thesis, human fetal brain tissue was studied in or-
der to increase our current knowledge of  authentic DA neurons. I therefore performed an extensive 
molecular, transcriptional and functional analysis of  human fetal DA neurons. Lastly, I used stem cells 
for replicating physiological DA development and maturation using the organoid technology. Differ-
ently from standard monolayer cell cultures, the organoid system allows cells self-structural organiza-
tion in three dimensional cultures, closely resembling the process taking place during development. 
14
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POPULÄRVETENSKAPLIG SAMMANFATTNING
Parkinsons sjukdom är den vanligaste rörelsehindrande, och den näst vanligaste neurodegenerativa 
sjukdomen efter Alzheimers sjukdom. De symptom som patienter ofta upplever är normalt relaterade 
till nedsatt motorfunktion, men en del patienter upplever neuropsykiatriska störningar, autonom och 
sensorisk dysfunktion, och sömnproblem. Det klassiska kännetecknet för Parkinsons sjukdom är 
förlusten av nervceller i hjärnan som under normala förhållanden kontrollerar motorsignaler genom 
att frisätta signalsubstansen dopamin.
Cellersättningsterapi har som mål att återställa funktionen och balansen i hjärnan som har gått för-
lorad hos patienter med Parkinsons sjukdom. Stamceller har förmågan att generera nervceller genom 
att applicera specifika protokoll i laboratoriet. Kliniska prövningar för Parkinsons sjukdom sker för 
närvarande med dessa celler, men stamceller har huvudsakligen kännetecknet av deras stora förmåga 
att dela sig i ett tidigt stadium vilket ger upphov till oro för tumörbildning. För närvarande undersöks 
även andra metoder som kan användas för att generera nervceller, såsom direkt omprogrammering av 
hudceller till så kallade inducerade nervceller. Det pågår även forskning där man riktar in sig på hjärn-
celler i hjärnan för direkt omprogrammering till önskade nervceller. Metoden direkt omprogrammer-
ing möjliggör generering av nervceller utan att genomgå ett proliferativt stadium, vilket minskar risken 
för tumörbildning.
En viktig aspekt att tänka på när man genererar nervceller för transplantationer är hur lika dessa 
nya celler är de äkta dopaminerga nervceller som är bosatta i människans hjärna. Vår kunskap om 
humana dopaminerga nervceller begränsas av hjärnvävnadens otillgänglighet under och efter utveck-
lingen. I min avhandling behandlade jag dessa olika aspekter av celltransplantation, och delade upp 
mitt arbete i två delar.
I den första delen av min avhandling fokuserade jag på att klarlägga egenskaperna för gen- och 
proteinuttryck tillsammans med funktionella aspekter av direkt omprogrammerade celler från män-
skliga hudceller eller mushjärnceller i den levande mushjärnan. I den andra delen av avhandlingen 
studerades människans fosterhjärnvävnad för att öka vår nuvarande kunskap om äkta dopaminerga 
hjärnceller. Jag utförde därför en omfattande molekylär, transkriptionell och funktionell analys av 
mänskliga dopaminerga hjärnceller från foster. Denna kunskap tillämpades sedan för att möjliggöra 
fysiologisk dopaminerg nervcellsutveckling och mognad med hjälp av organoidtekniken. Till skillnad 
från vanliga cellkulturer tillåter organoidsystemet cellerna att strukturera och organisera sig i tredi-
mensionella kulturer som efterliknar den process som äger rum under utveckling.
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RIASSUNTO IN ITALIANO
La malattia di Parkinson é la più comune tra i disordini del movimento e la seconda malattia 
neurodegenerativa dopo il morbo di Alzheimer. Solo il 10% dei casi riportati é correlato a mutazioni 
genetiche ed il restante 90% dei casi non ha una causa conosciuta. I sintomi sono generalmente 
collegati a difficoltá motorie, anche se sono stati riscontrati altri sintomi come disturbi neuropsichi-
atrici, disfunzioni del sistema nervoso autonomo e disturbi del sonno. La caratteristica principale della 
malattia é rappresentata dalla morte dei neuroni dopaminergici localizzati nel cervello che in con-
dizioni fisiologiche permettono la modulazione ed il controllo dell´attivitá motoria tramite il rilascio 
del neurotrasmettitore Dopamina.
La terapia con cellule staminali é un approccio che si basa sul trapianto intracerebrale di nuovi 
neuroni generati in laboratorio per permettere la ricostituzione delle funzioni dei neuroni dopamin-
ergici. Le cellule embrioniche staminali e pluripotenti sono studiate per la loro abilitá nel generare 
neuroni dopaminergici e sono attualmente implicate in studi clinici. Un alternativa all´uso delle cellule 
staminali é la riprogrammazione di cellule somatiche come le cellule della pelle. Questa tecnica pre-
vede l´espressione forzata di specifici fattori di trascrizione (TFs) o RNA messaggeri (miRNAs) che 
permettono il passaggio da un fenotipo cellulare ad un altro senza passare attraverso uno stato di pro-
liferazione. Questo aspetto é considerato un vantaggio rispetto all´uso delle cellule staminali in quanto 
limita la possibilitá di formazione di tumori. Inoltre, la riprogrammazione cellulare puó essere effettu-
ata direttamente nel cervello, somministrando TFs e miRNAs attraverso particelle virali. Quest´ultima 
applicazione prevede la riprogrammazioni di cellule che risiedono nel cervello ma che hanno funzione 
di supporto neuronale, permettendo di mantenere inattti i circuiti neuronali preesistenti. 
Un´ importante aspetto da considerare é quanto le cellule generate in laboratorio siano simili ai 
neuroni dopaminergici che si trovano nel cervello umano. Nonostante anni di ricerca, molti aspetti 
rigurado ai neuroni dopaminergici ancora non sono ancora chiari. Nella prima parte della tesi ho 
studiato neuroni generati da tecniche di riprogrammazione usando cellule e modelli animali. Nella 
seconda parte ho poi eseguito un´analisi dettagliata di neuroni dopaminergici ottenuti da embrioni 
umani. Questo ha permesso di accrescere l´ attuale conoscenza dello sviluppo del cervello umano per 
quanto riguarda i neuroni dopaminergici. Infine ho generato neuroni tramite il differenziamento di 
cellule staminali utilizzando organoidi, un sistema che mima lo sviluppo e la maturazione di neuroni 
in modo piú accurato rispetto ai sistemi tradizioni di colture cellulari. 
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ABBREVIATIONS
AAV  Adeno-Associated Vector
APs  Action Potentials
COMT  Catechol-O-methyltransferase
DA  Dopamine
DBS  Deep Brain Stimulation
DIV  Days In Vitro
FP  Floor Plate
GS3Ki  Glycogen Synthase 3 inhibitor
hESCs  Human Embryonic Stem Cells 
hiPSC  Human Induced Pluripotent Stem Cells
HLA  Human Leukocyte Antigen
iDANs  Induced Dopaminergic Neurons
iNs  Induced Neurons
LBs  Lewy Bodies
IsO  Isthmic Organizer
IZ  Intermediate Zone 
LV  Lentivirus
MAOB  Monoamine Oxidase Type B Inhibitor
mesDA  Mesencephalic Dopaminergic neurons
miRNA  micro RNA
MOI  Multiplicity of  Infection
MZ  Mantle Zone
ORF  Open Reading Frame
Patch-Seq  Patch-sequencing
PD  Parkinson’s Disease
PGK  Phosphoglycerate Kinase
PV  Parvalbumin
PSC  Pluripotent Stem Cells
REST  RE1-Silencing Transcription factor 
RG  Radial Glia
RMP  Resting Membrane Potential
scRNA-seq  Single Cell RNA Sequencing
shRNA  Short Hairpin RNA
SNpc  Substantia Nigra pars compacta
TH  Tyrosine Hydroxylase
TFs  Transcription Factors
VM  Ventral Midbrain
VTA  Ventral Tegmental Area
VZ  Ventricular Zone
wpc  Weeks Post Conception
w.p.i.  Weeks Post Injection
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INTRODUCTION
Parkinson´s Disease 
Parkinson’s Disease (PD) is the most common movement disorder and second most common 
neurodegenerative disorder after Alzheimer Disease, affecting around 1% of  the population over 60 
years of  age (de Lau and Breteler, 2006). The incidence of  PD reflects a correlation with age as 90% 
of  the cases are among 50 years or older individuals. However, an early onset of  the disease is also 
reported, with 10% of  the PD patients at the age of  21-49 years old (Mehanna et al., 2014).
PD is mostly seen in sporadic cases accounting for 90% of  the overall cases (Ascherio and Schwar-
zschild, 2016), nonetheless few causative monogenic mutations have been discovered (Greenamyre 
and Hastings, 2004). The symptoms experienced by patients were first described by James Parkinson 
in “An assay on the Shaking Palsy”, 1817, and they are nowadays well known to involve motor dys-
functions, such as tremor, rigidity, bradykinesia, hypokinesia, akinesia and freezing. Other symptoms 
such as neuropsychiatric disturbances, autonomic dysfunctions, sleep problems and sensory symp-
toms have been linked to PD (Kalia and Lang, 2015).
One disease feature is represented by formation of  abnormal protein aggregates, known as Lewy 
Bodies (LBs), firstly discovered in PD patients´ brains by Spillantini et al., 1997. LBs are mainly com-
posed by the a-synuclein protein that in physiological conditions retains functional roles in different 
neuronal subcellular compartments (Bendor et al., 2013). However, in pathological conditions it has 
been shown to spread in a prion-like manner between cells and brain regions (Braak et al., 2003) re-
cruiting functional proteins and favoring the process of  LBs formation. This leads to the disruption 
of  normal cellular functions related to mitochondrial, lysosomal and synaptic activity.
Another hallmark of  the pathology is represented by a loss of  mesencephalic Dopaminergic neu-
rons (mesDA) that reside in the Substantia Nigra pars compacta (SNpc) and connects to the caudate-
putamen in the basal ganglia circuit where they modulate motor output and control by releasing the 
neurotransmitter Dopamine (DA) (Björklund and Dunnett, 2007). The etiology of  mesDA death is 
still unknown, however LBs formation could represent one of  the factor contributing to neuronal 
death and PD progression (Stefanis, 2012).
Treatments and Therapies for PD
Current treatments are mainly characterized by drug administration including Levodopa, DA ago-
nists, Monoamine oxidase type B inhibitor (MAO-B) and catechol-O-methyltransferase (COMT). 
These treatments can restore dopaminergic activity in the striatum and alleviate the impaired motor 
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deficits of  PD patients. However, they do not treat many of  the non-motor features and they are as-
sociated with several side effects (Kalia and Lang, 2015). 
Another approach to treat PD is represented by deep brain stimulation (DBS), where electrodes 
are surgically implanted in the brain to deliver stimulating electrical signals for DA release. The dif-
ficult surgical procedure as well as a short action range of  the electrodes limit the application of  DBS 
for PD (Lozano et al., 2019).
Cell Replacement Therapy is an alternative approach to restore the function of  the dopaminergic 
neurons through the transplantation of  the lost cells. This field was initiated in the 1980´s when hu-
man fetal ventral midbrain tissue (VM) was transplanted intracerebrally into patients (Lindvall et al., 
1989). This treatment resulted in the restoration of  DA release and long-term clinical improvements 
in some patients (Lindvall et al., 1990, 1994; Wenning et al., 1997; Brundin et al., 2000; Barker et al., 
2015). Despite the positive results, the outcome has been very variable and graft-induced dyskinesia 
have been reported and hypothesized to be due to serotoninergic contaminant neurons in the graft. 
These complications, together with the restricted tissue availability, limit the use of  fetal VM in cell 
replacement therapy for PD. New renewable sources of  cells derived from stem cells such as human 
embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSC) have now been 
investigated and implicated in clinical trials for PD (Barker et al., 2017; Barker et al., 2018). 
A possible future source of  mesDA neurons is also represented by neurons directly converted 
from skin fibroblasts, so called induced neurons (iNs) (Caiazzo et al., 2011; Pfisterer et al., 2011). 
This process, known as direct reprogramming, is achieved via virus-dependent delivery of  specific 
transcription factors (TFs), micro RNAs (miRNA) and/or small molecules. It allows for short and 
cost effective protocols, favoring the possibility of  establishing personalized medicine. It also limits 
concerns regarding tumorigenicity which are present when using hESCs and hiPSCs. However, upon 
transplantation, low cell survival and integration have been reported (Kim et al., 2011; Caiazzo et al., 
2011; Dell’Anno et al., 2014). On the other hand, iNs have been shown to retain the aging signature 
of  the donor cells (Mertens, et al., 2015; Huh et al., 2016) and their potential application for cell dis-
ease modeling is been investigated (Drouin-Ouellet et al., 2017).
Another future venue for restoring neuronal functions in the brain is depicted by in vivo repro-
gramming of  resident cells. Indeed, non neuronal resident brain cells can be targeted through sys-
temic virus delivery and directly reprogrammed into the desired neuronal subtype (Buffo et al., 2005; 
Torper et al., 2013; Grande et al., 2013; Niu et al., 2013; Magnusson et al., 2014; Heinrich et al., 2014; 
Guo et al., 2014; Niu et al., 2015; O Torper et al., 2015; Liu et al., 2015; Brulet et al., 2017; Rivetti Di 
Val Cervo et al., 2017; Weinberg et al., 2017; Mattugini et al., 2019; Qian et al., 2020; Zhou et al., 2020). 
However, this promising approach has major challenges to be circumvent for clinical application, such 
as neuronal survival and innervation in injured or diseased brain and efficient reprogramming into 
human mesDA neurons.
 
DA neurons 
Generating DA Neurons trough in vitro technologies or via in vivo reprogramming requires mo-
lecular, transcriptional and functional understanding of  human mesDA neurons. Here a summary of  
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the current knowledge in these fields and highlights of  subjects that need to be investigated for mov-
ing forward in finding treatments for PD. 
 
Origin of  Dopaminergic Neurons
The mesDA neurons arise from the most ventral part of  the mesencephalon and they are derived 
from proliferating Radial Glia (RG) cells located in the ventricular zone (VZ) of  the medial floor 
plate (FP) (Figure 1)(Ono et al., 2007; Hebsgaard et al., 2009; Nelander et al., 2009). At the bound-
ary between the midbrain-hindbrain a signaling center, the isthmic organizer (IsO), is responsible for 
the expression of  the TF Otx2 (Millet et al., 1996; Broccoli et al., 1999) and for the secretion of  the 
morphogen Wnt1 in the midbrain (Nordström et al., 2002). These signals are essential in establishing 
the midbrain progenitor domain and the following mesDA neurogenesis (Ásgrímsdóttir and Arenas, 
2020). Upon specification, DA progenitors begin to express transcription factors required for mesDA 
neuron development, Foxa2, Lmx1a, Lmx1b (Andersson et al., 2006; Ferri et al., 2007; Nelander et al., 
2009; Marklund et al., 2014). These progenitors expand and subsequently undergo neurogenesis, a 
process regulated by the proneural genes Neurog2 and Mash1 (Kele et al., 2006) that results the genera-
tion of  post-mitotic mesDA neuroblasts that maintain the expression of  Otx2, Foxa2, Lmx1a/b and 
Figure 1 Schematic representation of midbrain dopaminergic neurons development and their gene expression at different 
stages. 
Abbreviations: VZ, ventricular zone; IZ, intermediate zone; MZ, mantel zone; mesDA, mesencephalic dopaminergic neu-
rons; RG, radial glia. 
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start to express new genes such as the TF Nr4a2 (Nurr1)(Zetterström et al., 1996; Ásgrímsdóttir and 
Arenas, 2020). Post-mitotic cells migrate from the VZ to the intermediate zone (IZ) and finally reach 
the mantle zone (MZ) where the mesDA post-mitotic cells mature into functional neurons secreting 
DA into their target. During this migration process, the cells acquire the expression of  other TFs re-
quired for mesDA neuron development, Pbx1 (Villaescusa et al., 2016), PITX3 and Engrailed1 (Smidt 
et al., 2004; Maxwell et al., 2005; Veenvliet et al., 2013). Maintaining the expression of  these key genes, 
cells subsequently are found to be enriched for genes related to DA function, such as the enzyme for 
DA production, tyrosine hydroxylase (TH), dopamine and monoamine transporters, Slc6A3/DAT and 
Slc18a2/Vmat2 (Molinoff  and Axelrod, 1971; Miller et al., 1999; Nelander et al., 2009). 
Transcriptional profile of  DA neurons
Adult midbrain DA neurons are traditionally classified based on their location and projection in 
two main subtypes. The A9 subclass, that populates the SN and is mainly involved in motor control 
and the A10 populations that populate the ventral tegmental area (VTA) and generates connections 
through the mesolimbic and mesostriatal pathways (Björklund and Dunnett, 2007). However recent 
studies have examined the molecular diversity of  mesDA neurons through transcriptional analysis 
at the single cell level, single cell RNA-sequencing (scRNA-seq) determining cell heterogeneity and 
developmental trajectories (Poulin et al., 2014; La Manno et al., 2016; Hook et al., 2018; Tiklová et 
al., 2020). These studies have almost exclusively been performed in mice where up to 7 different DA 
populations were found (Table 1)(reviewed in (Poulin et al., 2020). Only one study (La Manno et al., 
2016) has compared mouse and human development using scRNA-seq and profiled VM suggests 
the emergence of  3 different DA subtypes during early development. However in order to elucidate 
the exact molecular profile of  mesDA neurons, more studies should confirm these human mesDA 
developmental groups and correlate these populations with mature DA subtypes. 
Functional profile of  mesDA neurons
mesDA neurons in the SN make connections with the striatum through the nigrostriatal pathway. 
Here they modulate the activity of  medium spiny projection neurons releasing the neurotransmitter 
DA (Freund et al., 1984; Voorn et al., 1988). This modulation depends on the ability of  DA to activate 
D1-receptor expressing spiny neurons and inactivate D2- neurons. Activation of  dopaminergic neu-
rons is regulated through the presence of  D2 autoreceptors as well as NMDA receptors on mesDA 
dendrites and axons (GluR1 and AMPA) (Christoffersen et al., 1995; Albers et al., 1999). 
Studies from rat midbrain DA neurons suggest at least two distinct firing patterns among A9 and 
A10 neurons (Grenhoff  et al., 1988) with less regular discharge and more burst firing in the A10 
group (Ungless and Grace, 2012). Other characteristics such a resting membrane potential around 
-60 mV, threshold of  -41/-36 mV, long duration of  action potentials (APs) (>2 ms), input resist-
ance around 700-800 MW (Grace and Onn, 1989; Shepard and Bunney, 1991; Kang and Kitai, 1993; 
Pacheco-Cano et al., 1996) were characterized in DA neurons from rat slice preparations.
Furthermore, DA neurons are characterized by a unique pacemaking like firing: a slow membrane 
depolarizing conductance depolarizes the neuron from its resting membrane potential threshold for 
spike generation, typical of  DA neurons. The action potential (AP) is followed by a calcium-depend-
ent afterhyperpolarization followed by initiation of  a slow depolarization. However, detailed knowl-
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edge of  how human mesDA neurons function in vitro or in vivo and in relation to their transcriptional 
profile needs to be elucidated.  
Generating mesDA neurons in vitro
mesDA neurons from hESCs
hESCs were first successfully isolated from the inner cell mass of  the blastocyst (Figure 2) by 
Thomson et al 1988, a major breakthrough for developmental studies and cell replacement therapies. 
The main characteristics of  the derived cells are their infinite potential of  expansion in culture and 
their possible ability to differentiate into any of  the three germ layers cells upon cell-specific signals 
activation. Thereafter scientists succeeded in generating neurons through hESCs differentiation and 
embryoid body (EB) formation (Itskovitz-Eldor et al., 2000; Reubinoff  et al., 2001; Zhang et al., 
2001). 
An important improvement of  neuronal differentiation took place when a protocol for an opti-
mized neuralization was obtained (Chambers et al., 2009). This protocol is based on the addition of  
Nogging and SB431542 to inhibit bone morphogen proteins (BMPs) and blocking pathways of  Lefty, 
Activin and Transforming growths factor beta (TGFb). Along with the discovery of  the FP origin of  
the DA neurons, another group subsequently showed the possibility of  FP induction through the use 
of  Sonic Hedgehog (SHH) (Fasano et al., 2010). In this protocol, forebrain neurons were obtained. 
Only with the application of  patterning factors such as WNT through the use of  a chemical inhibitor 
of  glycogen synthase kinase 3 (GSK3) brought to the generation of  bona fide mesDA neurons (Kriks 
Genes
Location
Aldh1a1+
Sox6+
Vip+Aldh1a1+
 Otx2+
Vgat+Vglut+Vglut+Aldh1a1- 
Sox6+
TH
Aldh1a1
Sox6
Aldh1a7
Ndnf
Igf1
Sncg
Vcan
Anxa1
Grin2c
TH
Vip
Gipr
Calb1
Vglut2
TH
Aldh1a1
Otx2
Lpl
Neurod6
Gpr83
Grp
Cbln4
Vglut2
TH
Vgat
Calb1
Crhbp
Gad2
Wnt7b
Vglut2-
(Slc17a6)
Dat
TH
Vglut2
Calb1
TH
Vglut2
Calb1
TH
Sox6
Ndnf
Igf1
Sncg
Calb1
Lypd1
Tacr3
Cyp26b1
Ventral 
SNpc
Periaqueductal gray,
Dorsal raphe
Ventromedial
 VTA 
VTAVTADorsolateral
 SNpc
SNpc,
Parabrachial 
pigmented region 
of VTA,
Retrorubral area
Table 1 Classification of 7 dopaminergic clusters based on gene expression and localization. 
Table adapted from Poulin et al., 2020. Abbreviations: SNpc, substantia nigra pars compacta; VTA, ventral tegmental area.
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et al., 2011; Kirkeby et al., 2012; Nolbrant et al., 2017). These cells express the FP and midbrain mark-
ers such as OTX2, LMX1A, FOXA2 and TH, and they shows functional properties of  DA neurons 
and they integrate upon transplantation (Kriks et al., 2011; Doi et al., 2014; Grealish et al., 2015; 
Cardoso et al., 2018; Adler et al., 2019).
mesDA neurons from iPSC
In 2006 another groundbreaking discovery in the field of  pluripotent stem cell and development 
took place. Yamanaka and colleagues showed how mouse and human somatic cells can be repro-
grammed into iPSCs using virus mediated delivery of  four pluripotency factor (Takahashi et al., 
2007). This allows to revert any somatic cell into a pluripotent state and subsequent differentiation of  
this into any specific cell type. 
Of  particular importance, this discovery lead to the possibility of  generating patient specific lines 
or match human leukocyte antigen (HLA) donors for cell-based therapies. Such applications of  these 
cells are currently ongoing and results will answer key questions on functionality and integration of  
these cells (Barker et al., 2017; Parmar and Björklund, 2020).
Figure 2 Schematic overview of different cell sources used for therapies and studies of Parkinson´s Disease.
Abbreviations: mesDA, mesencephalic dopaminergic; ESC, embryonic stem cells; iPSC, induced pluripotent stem cells. 
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With this technique, fibroblasts or peripheral blood mononuclear cells (PBMCs) obtained from 
PD patients can be reverted back to pluripotency, and then differentiated into mesDA neurons al-
lowing to study cellular mechanisms related to the pathology, vulnerability, and degeneration of  these 
neurons (Figure 2).
mesDa neurons from skin fibroblasts
iNs are reprogrammed somatic cells that are forced to change their fate without passing through 
a pluripotent state (Figure 2) thanks to the viral delivery of  genes related to neuronal induction and 
maturation (Vierbuchen et al., 2010).
The main advantages of  direct reprogramming are represented by a fast protocol needed for the 
generation of  the neurons of  interest, a low risk of  genetic mutations insertion or tumor formation 
due to the absence of  a pluripotent step, a homogeneity of  the target population produced with low 
line to line variability and the possibility to resemble the patient-aged cellular phenotype (Tanabe et 
al., 2015). 
Several works have been carried out in order to generate dopaminergic (iDANs) neurons from 
somatic cells in vitro (Addis et al., 2011; J Kim et al., 2011; Caiazzo et al., 2011b; Pfisterer et al., 2011; 
Liu et al., 2012; Dell’Anno et al., 2014; Torper et al., 2015) indicating that different factor combina-
tions can successfully generate iDANs. The functionality of  these cells have been analysed in vitro and 
upon transplantation in animal models ( Kim et al., 2011; Caiazzo et al., 2011b; Dell’Anno et al., 2014) 
showing mature DA neuronal profile for iDANs generated from mouse skin fibroblasts or human fe-
tal skin fibroblast. Nevertheless studies applying direct reprogramming on human adult fibroblasts to 
neurons are very few (Table 2) and physiological activity of  direct reprogrammed DA neurons from 
human adult fibroblasts has been so far reported only in one study (Caiazzo et al., 2011) and transcrip-
tional studies to highlight differences and similarities with human mesDA neurons are still missing. 
Generating DA neurons in vivo 
In vivo reprogramming is based on the idea of  converting resident brain cells into a specific cell of  
interest that are impaired or lost in a diseased brain (Figure 2). A particular suitable target cell for this 
approach is represented by glia cells, proliferative and widely distributed cells in the brain parenchyma 
(Dimou and Götz, 2014). In vivo reprogramming eliminates the introduction of  external cells into the 
brain, avoiding the risk of  transplant rejection. Many studies have successfully generated neurons that 
acquire a diverse neuronal subtype, such as GABAergic, glutamatergic and DA phenotype (Grande 
et al., 2013; Niu et al., 2013; Torper et al., 2015; Rivetti Di Val Cervo et al., 2017). Recently published 
works showed improvements in the generation of  mesDA neurons by targeting the RNA-binding 
protein PTB in a chemically induced mouse model of  PD (Qian et al., 2020; Zhou et al., 2020) that 
resulted in high reprogramming efficiency and motor skills recovery. Whether these approaches will 
show similar results in different animal models of  PD will have to be addressed in the future, however 
these results provide further proofs supporting the use of  in vivo reprogramming as a restorative ap-
proach in PD.
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Caiazzo et al.
2011
Ladewig et al.
2012
Factor 
Combination
RNA- sequencing Functional 
assessment 
EfficiencyNeuronal 
Subtype 
Ascl1
Nurr1
Lmx1a
TUJ1+ 40.3% 36 ± 2.6
MAP2+ 35.1 ± 2.4, 
TAU+ 32.7% ± 3.1
Whole-Cell
Patch-Clamp
(details not specified)
Tuj1+ 5% ±1
TH+3% ±1
Dopaminergic
Hu et al.
2015
Ouellet et al.
2017
Yang et al.
2019
Ascl1
Ngn2
Small 
Molecules
Small 
Molecules
Ascl1
Brn2
shREST
Small 
Molecules
Small 
Molecules
Gabaergic
Glutamatergic
Glutamatergic
NA
Glutamatergic
bIII-tub+ 13.2% ±1.4
Tuj1+ and Map2+
Min 3.9 ±1.2
Max 12.6 ± 1.1
MAP2+ 40%  ca
TAU+ 50%  ca
NA
Whole-Cell
Patch-Clamp + 
Calcium Imaging
(co-culture active 
at 14 DIV)
Whole-Cell
Patch-Clamp
(co-culture active 
at 90-100 DIV)
NA
NA
NA
NA
Bulk
RNA-Seq
NA
Table 2 Reports of direct neuronal reprogramming of human adult skin cells into neurons (iNs) in vitro.
 Abbreviations: NA, not assessed; DIV, days in vitro.
Caiazzo, M. et al. (2011) ‘Direct generation of functional dopaminergic neurons from mouse and human fibroblasts’, 
Nature, 476(7359), pp. 224–227. doi: 10.1038/nature10284.
Drouin-Ouellet, J. et al. (2017) ‘REST suppression mediates neural conversion of adult human fibroblasts via micro-
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Ladewig, J. et al. (2012) ‘Small molecules enable highly efficient neuronal conversion of human fibroblasts’, Nature Meth-
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Yang, Y. et al. (2019) ‘Rapid and Efficient Conversion of Human Fibroblasts into Functional Neurons by Small Mol-
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Bridging the gap between in vitro and in vivo studies: 3D systems and or-
ganoids with midbrain profile
In 2013 the work from Lancaster et al., launched a new era in the research of  the human brain 
with the generation of  “cortical organoids”.  
These 3D structures are made of  self-organizing human PSCs that differentiate without pat-
terning factors (Kadoshima et al., 2013) giving rise to different brain regions including hindbrain, 
midbrain, forebrain and retinal cells in a single organoid. Remarkably, patterning events taking place 
in the organoids closely resembled the ones occurring in the brain (Renner et al., 2017). Variability 
in brain regions formation across organoids was however a limitation of  this protocol, resulting in 
new protocols involving patterning factors for generating selected brain structures such as the cortex 
(Sloan et al., 2018). More recently human midbrain organoids have been generated from regionally 
patterned neural stem cells (NSC) (Tieng et al., 2014; Jo et al., 2016; Qian et al., 2016; Monzel et al., 
2017; Kim et al., 2019; Smits et al., 2019). Cells committed to the FP identity of  the mesencephalon, 
have been subjected under 3D condition to specific spatio-temporal signaling following previously 
established protocols in 2D cultures (Kriks et al., 2011; Kirkeby et al., 2012; Reinhardt et al., 2013). 
The generated organoids showed the expression of  mature DA markers such as TH and DAT to-
gether with signs of  mature neuronal cells, as myelin formation (Faivre-Sarrailh and Devaux, 2013). 
Electrophysiological properties measured by Multi-Electrode Array (MEA) (Tieng et al., 2014) or 
with whole-cell patch-clamp recordings (Jo et al., 2016; Qian et al., 2016; Monzel et al., 2017; Kim et 
al., 2019) indicated presence of  mature network of  DA neurons. Ultimately functionality of  mesDA 
organoids was detected in form of  DA release (Smits et al., 2019) and presence of  Neuromelanin 
deposits (Jo et al., 2016). 
Overall, the use of  these systems supply a unique way for researchers to address transcriptional 
and functional questions in a human context, bridging the gap between in vitro cultures and animal 
models. 
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AIMS OF THE THESIS
The overall aim of  my thesis has been to assess the functionality and transcriptional profile of  
neurons derived from stem cells or via direct reprogramming in vitro and in vivo. A major focus has 
been to relate functional and transcriptional profile of  newly generated mesDA neurons in vitro and in 
vivo with the final aim to contribute to new cell-based therapies of  PD. 
The specific aims of  my thesis were to: 
1. Optimize the generation of  functional neurons from directly reprogrammed human adult skin 
fibroblasts in vitro (Paper I)
2. Generate DA neurons from healthy and PD human adult skin fibroblasts and assess their 
electrophysiological properties (Paper II)
3. Evaluate the profile of  newly reprogrammed neurons generated via AAV delivery of  DA fate 
determinants in animal models of  PD (Paper III)
4. Develop a 3D culture system for characterizing transcriptional and functional properties of  
human fetal VM DA neurons (Paper IV)
5. Analyse the ability of  a stem cell derived brain organoid system to retain molecular, functional 
and transcriptional characteristics of  the VM (Paper V)
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ADDITIONAL PAPERS AND REVIEW ARTICLES 
NOT INCLUDED IN THE THESIS
In addition to the papers included in this thesis, additional studies performed during my PhD studies 
have resulted in the following publications: 
Direct reprogramming intro interneurons: potential for brain repair.
Pereira M, Birtele M, Rylander Ottosson D.
Cellular and Molecular Life Science. 2019 Oct;76(20):3953-3967
In Vivo Direct Reprogramming of  Residual Glial Cells into Interneurons by Intracerebral Injections 
of  Viral Vectors.
Pereira M, Birtele M, Rylander Ottosson D. 
Journal of  Visualized Experiments. 2019 Jun 117;(148)
Single Cell Gene Expression Analysis Reveals Human Stem Cell-Derived Graft Composition in a Cell 
Therapy Model of  Parkinson´s Disease.
Tiklová K, Nolbrant S, Fiorenzano A, Björklund Å K, Sharma Y, Heuer A, Gillberg L,
Hoban D B, Cardoso T, Adler A F, Birtele M, Lundén-Miguel H, Volakakis N, Kirkeby
A, Perlmann T, Parmar M.
Nature Communication. 2020 11:2434
3D- Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices.
Kajtez J, Buchman S, Vasudevan S, Birtele M, Rocchetti S, Pless CJ, Heiskanen A, Barker A R,
Martinez-Serrano A, Parmar M, Ulrik Lind J U, Emnéus J.
Advanced Science. 2020, 202001150
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SUMMARY OF RESULTS AND DISCUSSION
Cell based therapies for PD rely on the capability of  differentiation and reprogramming protocols 
to successfully generate authentic mesDA neurons. To investigate this, I have been focusing on un-
derstanding functional and transcriptional properties of  newly generated cells as well as human fetal 
mesDA neurons. In paper I I show how human skin fibroblasts from adult donors can be directly 
reprogrammed into functional neurons in vitro. However, their subtype-specific identity resemble an 
heterogenous neuronal population. In the subsequent study, paper II, I focused on generating DA 
neurons in vitro via direct reprogramming of  human adult fibroblasts from healthy and PD donors. 
In paper III I applied the direct reprogramming technique in vivo and evaluated the profile of  newly 
generated neurons. However, reprogrammed neurons did not show the desired DA profile. Results 
from this study highlighted the gap between in vitro and in vivo experiments, leading to the need of  ex-
panding our knowledge in the DA neuronal development. We therefore established a relevant system 
where to study functional and transcriptional profile of  authentic VM neurons, paper IV. Lastly, in 
paper V, I set up a brain organoid model of  VM from hPSC to reproduce the generation of  authentic 
DA neurons. 
Improving functional maturation of  directly reprogrammed neurons 
from human adult fibroblasts in long term in vitro cultures (Paper I)
Neuronal conversion of  human adult cells into functional neurons is of  value for both disease 
modelling and patient-specific cell therapy treatments. However, reports have shown how human 
cells are harder to reprogram compared to rodent cells (Caiazzo et al., 2011; Xue et al., 2013, 2016) 
and how adult donors have lower reprogramming efficiencies compared to fetal cells (Pfisterer et 
al., 2011; Liu et al., 2013). To address this challenge, our group previously published a study show-
ing how the suppression of  the RE1-Silencing Transcription factor (REST) complex using a short 
hairpin RNA (shREST) is a key factor for generating neurons at high efficiency from human adult 
cells (Drouin-Ouellet et al., 2017a). In Ouellet et al., a single vector expressing shREST and the genes 
ASCL1 and BRN2 (AB-shREST), was developed. The neural conversion via AB-shREST was found 
to be in part, but not fully, mediated via microRNAs upregulation. This led us to investigate whether 
the AB-shREST cocktail together with miRNAs could improve the functional profile of  the new iNs. 
In this study, we decided to use an upregulation of  mir9 and mir124, already known to improve 
neuronal reprogramming (Yoo et al., 2011; Drouin-Ouellet et al., 2017), to see if  they were influenc-
ing the maturation of  cells when delivered together with our new “single vector” conversion protocol 
(Drouin-Ouellet et al., 2017a; Shrigley et al., 2018). 
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miRNAs added to the reprogramming factors increase the expression of  genes associated 
with neural development and cell communication at early stages of  the conversion
To investigate the effect of  miR9 and miR124 in the direct reprogramming of  human adult fi-
broblasts I performed global gene expression analysis of  fibroblasts converted with AB-shREST 
and cells converted using miR9 and miR124 in addition to Ascl1, Brn2, and shREST (AB-shREST-
miR9/124) at 5 days post-conversion. Results showed that a few genes associated with calcium signal-
ing (CACNG8, TNNT1, PALM3) were more highly expressed in the ABshREST-miR9/124 group 
(Figure 3A). Next, I performed similar analysis at 24 days after conversion and found that there was 
more divergent gene expression between the microRNA- and non-microRNA-reprogrammed cells 
(Figure 3B). Interestingly, comparing the gene expression between days 5 and 24, I found that synap-
tic or ion channel related genes SNAP29, PFN2, and FGF12 were increased significantly over time 
(Figure 3C). However, there were no signs of  physiological neuronal maturation at this time point 
with either conversion methods (Figure 4). This suggests that despite some differences in the expres-
sion of  genes related to neuronal maturation and synaptic function between the two conditions, none 
of  the conditions were functionally mature at this relatively early time point. 
In long term cultures, the expression of  miRNA9/124 together with shREST leads to iNs 
maturation and neuronal subtype specification 
Next, I analyzed the effect of  miR9/miR124 and shREST on functional maturation at a later stage 
of  the reprogramming process (Figure 5A). After 80 – 85 days in vitro the majority of  iNs converted 
Figure 3 Differential gene expression in iNs converted with AB-shREST-miR9/124 vs AB-shREST. 
(A) MA plot at day 5 indicating average gene expression of the samples AB-shREST-miR9/124 (n = 3) compared to AB-
shREST (n = 3). At this time point, genes related to ion and calcium regulation such as PALM3, CACNG8, and TNNT1 were 
found to be upregulated in the AB-shREST-miR9/124 condition. (B) MA plot at day 24 indicating average gene expression 
of the samples AB-shREST-miR9/124 (n = 3) compared to AB-shREST (n = 3). At this time point, the
general high divergence of gene expression can be found in between the conditions. (C) Plots of differential expression for 
genes related to neuronal maturation and function such as SNAP29, FGF12, SYT1, and PFN2 in AB-shREST-miR9/124 
samples at day 5 and day 24. Plots show an increase in these genes at day 24 in AB-shREST-miR9/124-converted cells.  
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Figure 4 Whole-cell patch-clamp recordings  of AB-shREST and AB-shREST-miR9/124 conditions at day 24. 
Bight field image representing patch pipette targeting a single neuron. Plot of RMP values from AB-shREST condition and 
AB-shREST-miR9/124 condition. Values show immature RMP for both conditions. Plots indicating the mean of RMP and 
relative SEM calculated from Student’s t-test analysis. (Upper figure) Examples of inward sodium/outward potassium cur-
rents from whole-cell patch-clamp recordings for AB-shREST condition (left panel) and AB-shREST-miR9/124 condition 
(right panel). All recordings showed an absence of currents. (Middle figure) Examples of induced APs from whole-cell 
patch-clamp recordings for AB-shREST condition (left panel) and AB-shREST-miR9/124 condition (right panel). All 
recordings showed an absence of induced APs. (Lower figure) Examples of spontaneous firing from whole-cell patch-
clamp recordings for AB-shREST condition (left panel) and AB-shREST-miR9/124 condition (right panel). All recordings 
showed an absence of activity.
with AB-shRESTmiRNA124/9 showed presence of  inward sodium currents (Figure 5B) and a higher 
proportion of  cells were capable of  firing current-induced APs (Figure 5C). Furthermore, the APs 
generated were of  higher amplitude in this group, indicating a greater maturation level in comparison 
with cells reprogrammed with miR9/124 or shREST only, in which only immature APs could be 
detected. In these iNs, the presence of  spontaneous firing was detected in current clamp mode, indi-
cating that the maturation level in this group was higher compared to the reprogramming conditions 
with miR9/124 or shREST only, where spontaneous firing was absent.
When looking for specific neurotransmitter phenotypes, cells showed a similar expression of  soma-
tostatin-, GABAergic-, glutamatergic-, acetylcholinergic-, and dopaminergic-related genes (SSTR1, 
GABRA1, GRIA2, CHRMA43, and DRD1) (Figure 5D).
Overall these data support the finding that mir9 and mir124 are involved in the neuronal matura-
tion, particularly it seems to improve functionality over long periods of  time when reprogramming 
human adult skin cells. The established approach results in functional neurons, however it does not 
seem to generate a single neuronal cell type but rather an heterogenous neuronal population. 
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Generating functional neurons with DA specific phenotype in vitro via 
direct reprogramming of  human adult skin fibroblasts from healthy and 
PD donors (Paper II)
Next, we investigated the possibility to generate dopaminergic neurons (iDANs) through different 
TFs combinations in addition to Ascl1, Brn2, and shREST. Our group previously showed the ability 
to directly reprogram human fibroblasts for generating DA neurons from different cell sources such 
as fetal skin, fetal lung and newborn foreskin (Pfisterer et al., 2011). In the same year, another group 
(Caiazzo et al., 2011) demonstrated the generation of  iDANs from mouse embryonic and human 
adult fibroblasts through the forced expression of  Mash1, Nurr1 and Lmx1a. However the extent 
of  the maturation levels of  these cells was not determined in iDANs derived from healthy and PD 
donors. 
Figure 5 Whole-cell patch-clamp recordings of iNs converted with different vectors at 80 DIV. 
(A) Representative immunofluorescence image showing TAU+ and MAP2+ cells on PFL coating at 60 DIV. (B) Repre-
sentative image of a patched iN and representative inward sodium/outward potassium electrophysiological recording of 
iNs reprogrammed using AB-shREST1-miR9/124. Quantification of Inward sodium current (AB-shREST, n = 9; AB-
miR9/124, n = 7; AB-shREST-miR9/124, n = 7) revealed higher sodium currents in AB-shREST-miR9/124 condition. (C) 
Quantification of the number of cells firing APs in each group
(AB-shREST, n = 9; AB-miR9/124, n = 7; AB-shREST-miR9/124, n = 7). (Upper figure) Example of mature induced AP 
in an iN cell reprogrammed using AB-shREST1-miR9/124 and immature induced AP present in an iN cell reprogrammed 
using AB-shREST. (Lower figure) Example of spontaneous firing present in the group ABshREST-miR9/124 and absence 
of spontaneous firing in the group AB-miR9/124. (D) Relative fold change expression for specific genes such as SSTR1, 
GABRA1, GRIA1, CHRNA3, and DRD1 indicating similar expression of neuronal subtype generated in both AB-shREST1 
(n = 3) and AB-shRESTmiR9/124 (n = 3) conditions.
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In this study my focus was to investigate how to efficiently generate iDANs with mature DA phe-
notype and functionally characterize iDANs generated from healthy and PD donors.
A combination of  known DA genes generates functional iDANs from human adult skin fi-
broblasts
We screened different reprogramming factors that were selected based on: their role during nor-
mal DA neurogenesis, their expression in human fetal ventral midbrain, and their role on midbrain-
specific chromatin modeling. All factors were expressed in combination with the knockdown of  
REST. The best TH+ cell yield was obtained with the combination that includes shREST, Ascl1, 
Lmx1a/b, Foxa2, Otx2, Nurr1(Figure 6A). This combination gave rise to 70.33 %± 0.31 % of  cells 
expressing the neuronal marker TAU+ of  which 16.1 % ± 2.01 expressed TH (Figure 6B).
Further characterization of  the iDANs showed that in addition to TH, these cells also expressed 
ALDH1A1, which is found in a subset of  A9 DA neurons that are more vulnerable to toxins as-
sociated with the development of  PD, and VMAT2 a key DA marker (Figure 6C). Gene expression 
profiling confirmed an up-regulation of  key genes related to the DA patterning and identity (FOXA1, 
OTX1, SHH, PITX3), as well as DA synaptic function including the receptors DRD1 to DRD5, the 
DA transporter DAT, the enzymes DDC, MAOA, ALDH1A1 and the A9-enriched DA marker 
Figure 6 Successful generation of iDANs from human adult fibroblasts.
(A) Overview of the protocol used for generating iDANs. (B) Quantification of TAU+ and TH+ cells (mean average of 
13,527 TAU+ and 2,826 TH+ cells assessed per well from 3 biological replicates). (C) Double TAU+ and TH+ iDANs 
expressing Aldh1a1 and VMAT2. Cells are counterstained with DAPI (in blue). (D) Gene expression quantification of DA 
genes relative to parental fibroblast levels (from 3 biological replicates). (E) Patch clamp recordings of iDANs (at day 65) 
showing presence of current induced APs, Inward NA+ - Outward K+ currents, selectively blocked signals with tetrodo-
toxin (ttx) and spontaneous firing.
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Figure 7 iDANs from PD and heathy donor lines.
(A) Quantification of TAU+ and TH+ cells (experiment has been repeated independently 3 times). Dashed lines represent 
the mean. (B) Double TAU+ and TH+ H-iDANs and PD-iDANs at day 60. Scale bar = 100μm. (C) Quantification of 
neurite profile in TAU+ H-iNs and PD-iNs. (D) Current-clamp recordings of evoked action potentials. (E) Quantification 
of current-clamp recordings of evoked action potentials (n = 8-10 neurons per lines, n = 5-6 lines per group). (F) Resting 
membrane potential of H-iNs and PD-iNs. (n = 4-9 neurons per lines, n = 5-6 lines per group). (G) Representative traces 
of Inward NA+- Outward K+ currents following voltage depolarization steps in H-iNs and PD-iNs. (H) Quantification of 
inward NA+ current (n = 4-9 neurons per lines, n = 5-6 lines per group). (I) Quantification of outward K+ current (n = 4-9 
neurons per lines, n = 5-6 lines per group).
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GIRK2 (Figure 6D). All of  these were present 25 days after initiation of  conversion. Moreover, the 
iNs showed mature electrophysiological properties 65 days post transduction. They displayed the 
ability to fire repetitive APs upon injection of  current as well as exhibited inward sodium (Na+) - out-
ward potassium (K+) currents with depolarizing steps (Figure 6E). When a continuous depolarizing 
voltage ramp was applied, the currents in the cells were specifically blocked by the neurotoxin tetro-
dotoxin (TTX), indicating an involvement of  voltage-gated sodium channels in the currents. Further-
more, cells displayed spontaneous firing at resting membrane potential, indicating a mature profile.
Neuronal Reprogramming is successfully achieved from healthy and sporadic PD donors
Next, we investigated whether iDANs could be successfully generated from healthy and sporadic 
PD donors. We reprogrammed 10 healthy cell lines and 19 sporadic PD lines and we found that 
fibroblasts obtained from PD patients reprogrammed at a similar efficiency to those obtained from 
age- and sex-matched healthy donors and displayed a similar neuronal morphological profile (Figure 
7 A-C). Moreover, when measuring their functional properties with patch-clamp electrophysiological 
recording, we confirmed that iNs derived from healthy donors (H-iNs) and from PD patients (PD-
iNs) displayed similar functionality in terms of  the number of  current induced APs (Figure 7 D-E), 
resting membrane potential (Figure 7 F) and the inward Na+- outward K+ current (Figure 7 G-I).
In this study, we generated subtype specific iNs directly converted from human fibroblasts using 
a new combination of  transcription factors that resulted in DA neurons. We found that fibroblasts 
from both healthy controls and PD patients converted into functional neurons at similar degree.
Application of  direct reprogramming in vivo: turning resident glia into 
neurons (Paper III)
In order to investigate the potential of  direct reprogramming in vivo, we sought to convert resident 
NG2 glia cells into functional and subtype specific neurons by delivery of  reprogrammed factors 
in the brain. To this end we made use of  factors that have been previously used for dopaminergic 
conversions, Ascl1, Lmx1a and Nurr1 (ALN)(Caiazzo et al., 2011). At 12 weeks post injection (w.p.i.) 
we analyzed molecular, functional and gene expression of  the reprogrammed neurons in order to 
characterize their profile. 
In vivo conversion using ALN combination give rise to mature neurons with interneuron 
phenotype
We performed the delivery of  CRE-dependent ALN conversion vectors into NG2-Cre mice with 
a GFP reporter that labels reprogrammed neurons. 
At 12 w.p.i. we estimated the neuronal conversion efficacy as being 66.81% ± 38.38%. Immunohis-
tochemical analysis revealed the presence of  markers common to interneurons (IntNs) such as Par-
valbumin (PV), choline acetyltransferase (ChAT), Neuropeptide Y (NPY), or the striatal projection 
neuron marker DARPP32 (Figure 8A). Quantifications showed that the majority (41.27% ±2.99%) 
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co-expressed PV, whereas less than 10% of  the GFP+ cells were co-labeled with any of  the other 
markers (Figure 8B). These data were confirmed by laser capture microscopy (LCM) (Figure 8C) and 
functional assessment. Interestingly, similar results were found in animal models of  PD where DA 
denervation in the SNpc was obtained through 6-OHDA toxin injection. 
Figure 8 Phenotypic Identities of In Vivo Reprogrammed Neurons.
(A) Confocal images showing co-localization of GFP and the interneuron markers PV, ChAT, NPY , and projection neuron 
marker DARPP32.
(B) Percentage of neurons expressing the markers from (A) shows that the majority of ALN-converted neurons are PV+ 
(n = 9 brains).
(C) RNA-seq results, presented as average RPKM (reads per kilobase per million) values, show the downregulation of 
glial genes and upregulation of pan-neuronal genes and interneuronal-linked genes (n = 12–65 cells from n = 2–3 brains).
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Delivery of  different factor combinations results in similar interneronal phenotype
Next, we investigated the reprogramming output using additional factors combinations with pro-
neural (Ascl1, Ngn2, NeuroD1) and DA-(Lmx1a, Nurr1, FoxA2, En1) genes (Figure 9A). Four differ-
ent combinations were used, NgLN (Neurogenin2, Lmx1a, and Nurr1), ANgN (Ascl1, Neurogenin2, and 
Nurr1), NgND1 (Neurogenin2 and NeuroD1), and AFLE (Ascl1, FoxA2, Lmx1a, and En1) (Figure 9B). 
These were injected either alone or together with the midbrain-specific chromatin remodeler Smarca1 
(Metzakopian et al., 2015) into the striatum of  intact NG2-CRE mice. Similar to ALN, the largest 
proportion expressed the interneuron marker PV, ChAT+ and NPY+ neurons were found in lower 
percentages and CTIP2 was found in less than 10% of  the reprogrammed neurons (Figure 9C).
Here we showed that we can generate functional neurons through in vivo direct reprogramming, 
supporting its application for brain repair. However, when delivering different factors combinations 
previously used for generating TH neurons from fibroblasts and astrocytes in vitro, no TH-expressing 
neurons were generated via in vivo reprogramming. This raises the question of  how cell fate is influ-
enced during in vivo conversion and poses the issue of  establishing appropriate in vitro systems to bet-
ter investigate fate determinants for reprogramming studies. 
Figure 9 Different Gene Combinations Expressed in Striatal NG2 Glia Lead to Minor Differences in Neuronal Phenotype.
(A) Schematics of AAV5 constructs used for in vivo reprogramming.(B) Genes were grouped into four different combina-
tions: NgLN, ANgN, NgND1, and AFLE. These groups of factors were used alone or in
combination with Smarca1a. (C) Quantification of neurons reprogrammed with different factor combinations that express 
the markers PV, ChAT, NPY, GAD65/67, and CTIP2 shows that the majority of neurons obtained are PV-positive in all 
conditions (n = 3 brains/combination).
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Developing a 3D culture system to study human fetal dopaminergic neu-
rons (Paper IV)
Efforts to develop more refined and precise reprogramming and differentiation protocols to gen-
erate sub-type specific DA neurons both in vitro and in vivo are continuously ongoing. In this process, 
a better understanding of  human DA neuron specification and maturation is vital.
Figure 10 Three different Human Dopaminergic Trajectories are revealed during fetal development. 
(A) UMAP embedding of integrated data set from four embryos shows presence of 9 different clusters: Dopamine Neurons 
(Dopa Neurons), Glutamatergic/Serotoninergic Neurons (Glut/Serot), Microglia, Radial Glia 1 and 2 (RG-1, RG-2), Ocu-
lomotor/Trochlear Nucleus (OTN nucleus), Pericytes/Endothelial Cells (Peri/Endo), Progenitors (Prog) and Red Blood 
Cells (RBC). (B) UMAP embedding of dopamine neurons from all time points (n=3838) colored by sample identity. Re-
sults identify integration and overlapping expression among embryos at 6, 8, 10.5 and 11.5 weeks PC. UMAP embedding 
of dopamine neurons from all time points (n=3838) colored by cluster. Six putative dopaminergic subtypes are found to 
be expressed in embryos at 6, 8, 10.5 and 11.5 weeks PC. (C) Featureplot of normalized expression for selected dopamine 
neuron marker genes, TH, LMX1A, KCNJ6, CALB1. Purple indicates high expression. Dopaminergic Markers are found to 
be highly expressed in cluster 1, 2, 3, 6. (D)Three lineage trajectories were identified by Slingshot Analysis, with cluster 
5,4 and 2 as common path and 3,1 and 6 as leaf clusters. UMAP plot showing the arrangement of cells in pseudotime ac-
cording to the three trajectories. 
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Human fetal tissue is of  great value for understanding the human brain development. Previously 
this tissue has been characterized in 2D culture conditions (Hebsgaard et al., 2009; Nelander, et al., 
2009) for its gene and protein profile. 
In this study we wanted to explore if  it is possible to culture hVM cells in 3D organoid-like cul-
tures, with the aim of  maintaining fetal DA neurons in long term cultures. Ultimately, we wanted to 
characterize fetal human VM-derived DA neurons at the level of  gene expression, phenotypic identity 
and functional properties. 
Distinct dopaminergic trajectories are found in the developing human brain
To determine the cellular composition of  the developing VM at the molecular level, we subdis-
sected VM from human embryos of  gestational ages 6 to 11.5 weeks post conception (wpc). We 
performed droplet based scRNA-seq on the dissected VM tissue from 4 separate fetuses (6, 8, 10 
and 11.5 wpc) (Figure 10A). Among different embryos we were able to find 6 different DA clusters 
(Figure 10B-C), suggesting the presence of  transcriptionally distinct dopaminergic subtypes at these 
early timepoints.
When applying Slingshot analysis (Figure 10D), three different trajectories were found to link the 
DA clusters, pointing at different developmental pathways in the DA generation. 
Figure 11 Dopaminergic development is not sustained in 2D culture systems 
(A)Immunostaining of hVM 2D cultures at d15 for TH, post-mitotic DA neuronal marker, showing presence of DA neu-
rons in culture, at d30 TH marker is not expressed and low levels of MAP2 are found. (B) Feature plots from scRNA-seq 
analysis of 2D cultures at d15 and d30 for TH showing a decrease in the expression over time. (C) Immunostaining of 
hVM 3D cultures at d15 for TH, showing presence of DA neurons in culture, at d30 TH marker is expressed at high levels. 
(D) Feature plots from scRNA-seq analysis of 3D cultures at d15 and d30 for TH showing a stable expression over time.
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Figure 13 Single cell transcriptomics and whole-cell patch clamp recordings of standard VM organoid.
(A) UMAP plot showing clustering of 91,034 analysed cells from VM organoids at day 15, 30, 60, 90, and 120. Clusters 
identified: neural progenitors, floor plate progenitors, DA neurons, astrocytes, oligodendrocytes and vascular leptomenin-
geal cells.  (B) Electrophysiological properties of externally and internally located neurons within standard VM organoids 
demonstrating inner core immaturity by whole-cell patch-clamp recordings.
A
B
<- Figure 12 3D system allows transcriptional and functional studies oh human DA neurons in long term cultures.
(A) Representative images showing patch pipette targeting a single cells during whole-cell patch-clamp recording, fol-
lowed by cell aspiration from the 3D hVM culture for scRNA-seq preparation. (B) Traces from whole-cell patch-clamp 
recordings showing induced APs, repetitive firing upon small current injection and spontaneous firing. Cells presenting 
induced APs, repetitive firing and spontaneous firing were classified as Firing Cells Dopaminergic, cells that presented 
only induced APs were classified as Firing Cells Not Dopaminergic. In the analysis was included also one cell, here not 
presented, that did not show any induced APs and classified as Not Firing. (C) Heatmap showing single cell expression 
for selected genes (progenitors, pan-neuronal and dopaminergic) in each recorded cell. Different transcriptional profile is 
visible among Dopaminergic, Not Dopaminergic Firing cells and Not Firing cell.  (D) UMAP plot showing DA subclus-
ters from hVM not cultured resulted in the 10x dataset merged with Patch-Seq Smartseq processed cells. Majority of the 
patched cells with a mature profile cluster within the late DA populations observed in 10x data.
Repetitive firing
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Over long period of  time DA neurons are better preserved in 3D cultures than standard 2D 
system
When culturing the human fetal VM, we found that over time, DA neurons were lost in the cul-
tures, as shown by the loss of  TH-positive cells from scRNA-seq and immunocytochemistry analysis 
(Figure 11A-B). We therefore optimized a protocol for self-aggregation using low attachment plates 
to obtain cell-cell self-interaction. In stark contrast to the in 2D cultures, in the 3D condition the TH 
neurons were shown to be maintained at day 30 (Figure 11C-D). 
3D culture system enable to capture different molecular subtypes of  functionally mature hu-
man DA neurons
In an attempt to relate molecular subtype to functional properties, we performed Patch-Sequenc-
ing (Patch-Seq) on fetal DA neurons from 3D cultures at day 30 (n=6) (Figure 12A). We found that 
cells presenting dopaminergic firing (Figure 12B) displayed higher expression levels for genes related 
to dopamine pathway such as TH, SLC32A1, CALBINDIN and their transcriptome was clearly dif-
ferent from non-DA neurons. Specific ion channels and receptors were also found to be upregulated 
in the dopaminergic firing cells (Figure 12C). The cell that did not show the ability to fire evoked APs, 
did not express any of  the dopamine markers expressed by the firing cells .
When merging the dataset from Patch-seq and 10x of  fetal VM, the majority of  patched cells (in 
red) are overlapping with the late DA neurons confirming that the late DA neuron cluster indeed is 
representing a functionally mature DA population (Figure 12D). 
In this work we found that fetal DA neurons cluster in 6 different groups that appeared to follow 
distinct development trajectories. Next we established a culture condition that allowed us to maintain 
and analyse human mature DA neurons in culture. This enabled us to study the physiology and tran-
scriptional profile of  mature DA neurons that resembled the characteristics of  a late developmental 
stage of  DA neurons.
 
Establishing VM organoids from PSCs as a source of  authentic DA neu-
rons (Paper V) 
In this study, we wanted to generate mesDA neurons from hESC in an organoid system to under-
stand the physiological characteristics of  the midbrain organoids, as well as their affinity with fetal 3D 
VM organoids. Here we adapted a commonly used protocol for forebrain organoid generation with 
the addition of  dual-SMAD inhibition (Nolbrant et al., 2017), combined with exposure to the neural 
tube ventralizing secreted factor SHH and GSK3i. GSK3i activates Wnt signaling, thereby promoting 
neurogenic conversion of  VM FP progenitors toward DA neuron fate in standard 2D differentiations 
(Nordström et al., 2002). 
Human DA neurons are successfully generated in VM organoids
scRNAseq analysis of  generated organoids revealed the presence of  a neuronal cluster defined by 
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expression of  DCX, SYT1, STMN2 and primarily expressed genes associated with DA fate identity 
(PBX, NR4A2, EN1, TH, DDC). VM organoids also contained astrocytes (GFAP, AQP4, EDNRB) 
and a small group of  oligodendrocyte progenitors (OLIG1/2, PDGFRa, SOX10), as well as a newly 
discovered class of  perivascular-like cells termed vascular leptomeningeal cells (VLMCs) expressing 
PDGFRa, COL1A1, COL1A2, and LUM (Marques et al., 2016; Vanlandewijck et al., 2018) (Figure 
13A). However, when analyzing the functional activity of  VM organoid, we found that the system 
used did not support a homogenous differentiation. Indeed, as revealed by absence of  Inward So-
dium/Outward Delayed Rectifier Potassium currents, and lack of  ability to fire induced APs (Figure 
13B), the inner core of  the organoid was found to be differentiated to a less extent compared to the 
outer layers.
Silk-bioengineered VM organoids allows for homogeneous and reproducible pattering
To address the limitation of  immature inner core and variability in terms of  TH yields among 
organoids, we used a biomaterial made of  recombinant spider silk protein (Widhe et al., 2010; Åstrand 
et al., 2020) which functions as a biocompatible and bioengineered cell scaffold. Silk fibers were used 
either alone or functionalized with Lam-111 (termed silk(-) and silk(+)), shown to promote DA pat-
terning and support DA differentiation in 2D cultures. scRNAseq and immunohistochemical analysis 
of  silk hVM organoids revealed a similar developmental progression and similar cell populations to 
that observed in conventional organoids. To support this data, functional analysis was performed us-
ing whole-cell patch-clamp recordings and revealed mature DA neurons in both inner and outer layer 
of  the organoids (Figure 14). DA release was analysed from standard and silk hVM organoids and 
confirmed the high maturation and functionality of  DA neurons. In conventionally generated orga-
Figure 14 Silk-VM organoids are functionally homogenous.
(A)Whole-cell patch-clamp recordings of external and internal silk+Lam111 VM showing presence of mature neurons 
both in the internal and external region of the organoids. (B) Representative analysis of real-time DA release chrono-
amperometric measurements in conventional and silk+Lam111 organoids showing less variability in DA release in Silk-
VM organoids.
A
B
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noids, only four out of  eight VM organoids recorded showed a release of  DA while seven out of  eight 
silk+Lam111 organoids released DA (Figure 14B). Although the quality of  DA neurons generated in 
3D organoids is comparable between conventional and silk organoids, the silk-based tissue engineer-
ing technology is more robust and results in less variation within and between organoids. 
This work shows how hVM brain organoids optimized with Silk scaffold were efficiently pat-
terned into a VM identity, leading to the formation of  DA progenitors and their subsequent differen-
tiation into mature DA neurons with electrophysiological properties of  DA neurons and the ability to 
release the neurotransmitter DA. 
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CONCLUSIONS AND FUTURE PERSPECTIVES
DA neurons play an essential role in PD as they are found to be selectively lost in the SNpc and 
their main released neurotransmitter, DA, is found to be present at lower levels in patients when 
compared to healthy individuals (Dauer and Przedborski, 2003). Indeed studies that allow restoration 
of  these cells in the brain and aim at understanding the causes of  this selective loss are essential for 
progressing towards finding a cure for PD. 
To allow such studies, a generation of  bona fide DA neurons is vital and a detailed characterization 
of  the newly generated neurons is essential for their application in pre- and clinical context. 
In paper I, direct neuronal reprogramming was applied to human adult fibroblasts with the aim 
of  achieving cells capable of  neuronal maturation and function for future applications. Indeed, only 
few studies previously provided successful neuronal maturation from in vitro reprogramming of  hu-
man adult skin fibroblasts (Caiazzo et al., 2011; Drouin-Ouellet et al., 2017b). Global gene expression 
analysis at 5 and 24 DIV showed that using miR9 and miR124 in addition to Ascl1, Brn2, and shREST 
as reprogramming factors correlates with an upregulation of  genes related to calcium and functional 
neuronal properties. However, at these time points cells were not functionally active. Only between 
80-90 DIV cells displayed neuronal activity, with a more pronounced mature neuronal population in 
miR9/miR124, Ascl1, Brn2, shREST reprogrammed neurons. These results indicate that reprogram-
ming of  human adult neurons requires a long culturing period to reach maturation when applying 
Ascl1, Brn2, and shREST. The presence of  mir9 and mir124, factors previously used for reprogram-
ming studies (Yoo et al., 2011), here helped the maturation process leading to a high degree of  func-
tionality that was reported for the first time in the context of  human adult skin cells reprogramming. 
Furthermore, gene analysis of  late time points showed a heterogeneous neuronal profile present in 
the cultures, indicating that the expressed genes activate an intracellular cascade related to a pan-
neuronal profile. In the future, a superior characterization of  the iNs cultured together with other 
cell types, such as astrocytes, will help in determining if  they retain the ability to form circuits and 
complex cell to cell interactions, aspects that are essential for both cell transplantation and disease 
modelling.
In Paper II direct reprogramming was used for generating DA neurons from human adult skin 
cells. Similar to the work from Caiazzo et al. 2011, a successful conversion into DA neurons was 
achieved, however, in this work a new factor combination was found to reprogram both healthy and 
diseased skin adult samples with high neuronal yield. The newly generated cells showed the expres-
sion of  pan-neuronal as well as DA specific proteins. Functional analysis showed that reprogrammed 
cells from healthy and PD derived fibroblasts retain a similar neuronal maturation. These results 
confirm the successful establishment of  a protocol for iDANs generation. Subsequent analysis of  
the reprogrammed neurons showed impairment of  different autophagic pathways in iDANs gener-
ated from PD fibroblast lines, supporting previous findings that show maintenance of  epigenetic and 
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phenotypic signatures during direct reprogramming (Mertens et al., 2015). Finally, these results show 
how this protocol can have applications for disease modeling studies, however it provides indications 
that cell transplantations for PD patients may require HLA matched donors for the generation of  
healthy iDANs.
In Paper III we applied direct reprogramming for generating DA neurons in vivo. Mouse resi-
dent NG2 glia was targeted and successfully converted into neurons when delivering Ascl1, Lmx1a 
and Nurr1 as reprogramming factors. Interestingly, the factor combination that in vitro generates DA 
neurons, here gave rise to interneurons, mostly with properties of  PV+ cells. To explore the pos-
sibility that environmental cues could affect the reprogramming output, injections of  ALN factors 
in a 6-OHDA model of  PD were performed. However, no TH+ cells were detected, but rather cells 
converted to an interneuronal phenotype were assessed in the reprogrammed cells. In addition, when 
delivering ALN but also other factor combinations, PV+ interneurons were found to be the main 
cell type generated through reprogramming. These results mark the gap between in vitro and in vivo 
outcomes in reprogramming studies. This study is therefore pointing at a need for new models where 
to study and generate DA neurons in a human physiologically relevant context. 
Generation of  mesDA neurons from stem cells reprogramming is often based on current knowl-
edge regarding hVM formation and maturation, however, the restricted access to human material 
during brain development limits a deep understanding of  the development of  this brain region. 
In paper III, I explored the possibility to study human fetal VM to expand our knowledge of  
mesDA neurons. With this work, I provide insights into dopaminergic diversity among human em-
bryos collected at different developmental stages. A similar approach has been adopted in the study by 
La Manno et al., nonetheless here the yield of  cells collected for scRNA-seq was improved, generating 
a robust dataset composed by more than 20´000 hVM fetal derived cells. Furthermore, I cultured hu-
man fetal VM for allowing cell specification and maturation. Previous works (Hebsgaard et al., 2009; 
Nelander et al., 2009; Ribeiro et al., 2013) showed the possibility to culture human fetal VM tissue in 
2D for a short period of  time. Here, 3D culturing resulted in a successful approach for maintaining 
DA neurons alive outside the human embryo up to 4 months. Lastly, DA neurons were characterized 
by Patch-Seq technique resulting in gene and functional analysis of  mature DA neurons. 
These results provide a valuable tool that can be used as a reference dataset when generating or 
studying human mesDA neurons. 
In Paper V, the generation of  neurons that resemble authentic mesDA development was assessed 
in VM organoid. Organoid system represent a technique that has been recently applied in the field of  
Neuroscience (Lancaster et al., 2013). Generation of  organoids with characteristics of  specific brain 
regions has been achieved through the use of  specific patterning protocols (Renner et al., 2017; Sloan 
et al., 2018). Similarly to other works (Tieng et al., 2014; Jo et al., 2016; Qian et al., 2016; Monzel et al., 
2017; Kim et al., 2019; Smits et al., 2019) VM organoids were here successfully established. Further-
more in this study an inner undifferentiated core was found, limitation that is commonly known in 
the field (Qian et al., 2019). Therefore, a new culturing method that employs the use of  silk microfib-
ers was implemented and resulted in VM organoids that homogenously resemble gene, protein and 
functional profile of  authentic DA neurons.
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Overall, the studies in this thesis show how transcriptional and functional analysis are applied for 
studying DA neurons and for establishing the authenticity of  DA neurons generated through repro-
gramming and differentiation studies. Indeed transcription and function are two essential aspects to 
be determined when generating neurons for therapeutic applications. These features are used in a 
comparison between newly generated and authentic mesDA. However, most of  our current knowl-
edge on the DA populations is based on rodent studies and/or performed with underpowered tech-
nologies. To allow a better understanding of  human DA neurons, I established a 3D system to study 
single-cell transcriptome and physiological profile of  human fetal VM. Finally, PSCs VM organoid 
were estabished for generating autentic mesDA neurons. This provide evidence that VM organoids 
can be used for future applications aiming at bridging the gap between in vitro and in vivo studies.
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MATERIALS AND METHODS
In this chapter, I will describe key methods used in the studies that are included in my thesis. For ad-
ditional details about these procedures and others not referred here, I kindly refer the reader to the 
method section of  the respective papers (see appendix). 
In vitro direct reprogramming
Culturing of  human fibroblasts
Adult dermal fibroblasts were obtained from the Parkinson’s Disease Research clinic at the John 
van Geest Centre for Brain Repair (Cambridge, UK) and used under local ethical approval (REC 09/
H0311/88). For biopsy sampling information see Drouin-Ouellet et al., 2017. Fibroblasts were ex-
panded in T75 flasks with standard fibroblast medium (DMEM, 10% FBS, 1% penicillin-streptomy-
cin) at 37°C in 5% CO2. After thawing, cells were kept a minimum of  2 days in culture before starting 
experiments. When confluent, the cells were dissociated with 0.05% trypsin and plated at a lower den-
sity for expansion. To freeze the fibroblasts from a confluent T75 flask, the cells were detached after 5 
minutes incubation in 0.05% trypsin 37°C, spun for 5 minutes at 400g and frozen in a 50/50 mixture 
of  DMEM and FBS with 10% DMSO. For details of  cell lines used in Paper I and II see Table 3.
Lentiviral Vectors
The lentiviruses (LV) used are third generation vectors containing a non-regulated ubiquitous 
phosphoglycerate kinase (PGK) promoter. In Paper I the DNA plasmids used are expressing the 
open reading frames (ORFs) for Ascl1, Brn2 with short hairpin RNA (shRNA) targeting REST or 
ORFs for Ascl1, Brn2 with miRNA loops for miR-9/9* and miR-124 in combination with shRNA 
targeting REST. The single vector containing Ascl1, Brn2, shREST was used at multiplicity of  infec-
tion (MOI) of  20. The vector containing Ascl1, Brn2, miR9/9* and miR124 was used in combination 
with shRNA targeting REST at MOI 20. All viruses used in this study titered between 3 x108 and 6 
x109 pfu/mL. In Paper II DNA plasmids expressing ORFs for Ascl1, Lmx1a, Lmx1b, FoxA2, Otx2, 
Nurr1, Smarca1, CNPY, En1 or Pax8, as well as two shRNAs targeting REST containing a non-regu-
lated U6 promoter. The single vector containing Ascl1, Brn2, shREST was used to reprogram iNs for 
RNAseq. Transduction was performed at a MOI of  5 for each vector (all viruses used in this study 
titered between 1 x 108 and 9 x 109) or MOI of  20 in the case of  the single vector containing Ascl1, 
Brn2, shREST.
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Table 3 Details of human fibroblasts used in these studies.
Group Sex Age at biopsy Age of onset Study 
Healthy M 69  Paper II 
Healthy F 67  Paper I and II 
Healthy M 80  Paper II 
Healthy F 75  Paper II 
Healthy M 70  Paper II 
Healthy F 70  Paper I and II 
Healthy M 71  Paper II 
Healthy F 61  Paper II 
Healthy F 66  Paper II 
Healthy F 58  Paper II 
PD M 56 34 Paper II 
PD M 60 48 Paper II 
PD F 77 65 Paper II 
PD F 67 56 Paper II 
PD F 59 45 Paper II 
PD F 80 69 Paper II 
PD M 80 49 Paper II 
PD F 87 72 Paper II 
PD F 77 56 Paper II 
PD M 75 63 Paper II 
PD M 77 66 Paper II 
PD F 71 62 Paper II 
PD M 72 70 Paper II 
PD M 81 76 Paper II 
PD F 44 40 Paper II 
PD F 79 NA Paper II 
PD M 61 60 Paper II 
PD F 68 55 Paper II 
PD M 57 50 Paper II 
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Neuronal Reprogramming 
Fibroblasts were plated at a density of  27 800 cells per cm2 in 24-well plates (Nunc). Cells used 
for electrophysiological recordings were directly plated on glass coverslips coated with Polyornithine 
(15 µg/mL), Fibronectin (0.5 ng/µL) and Laminin (5 µg/mL) (PFL). One day after plating, cells were 
transduced with Lentiviral Vectors with fibroblast medium. Three days after the viral transduction, 
the medium was replaced with neural differentiation medium (NDiff227; Takara-Clontech) supple-
mented with growth factors at the following concentrations: LM-22A4 (2 µM, R&D Systems), GDNF 
(2 ng/mL, R&D Systems), NT3 (10 ng/µL, R&D Systems) and db-cAMP (0.5 mM, Sigma) and the 
small molecules CHIR99021 (2 µM, Axon), SB-431542 (10 µM, Axon), noggin (0.5 µg/ml, R&D Sys-
tems), LDN-193189 (0.5 µM, Axon), valproic acid sodium salt (VPA; 1mM, Merck Millipore). Half  
medium changes were performed every 2 days for the first 30 days of  conversion, whereas in the later 
stages of  conversion the medium changes were done every 3 days. At 18 days post-transduction, the 
small molecules were withheld, and the neuronal medium was supplemented only with LM-22A4, 
GDNF, NT3 and db-cAMP until the end of  the experiment. 
In vivo direct reprogramming
Transgenic animals
GFAP-Cre (Jackson) transgenic mice were backcrossed onto a C57BL/6J background, and NG2-
Cre (Jackson) transgenic mice were backcrossed onto a B6129PF2/J background, bred at the in-house 
BMC animal facility. Heterozygotes were identified by PCR.
Viral Vectors
Cre-inducible AAV5 vectors were created by inserting the cDNA for the genes of  interest in a 
reverse orientation flanked by two pair of  heterotypical, antiparallel LoxP (FLEX) sequences. Con-
structs were mixed in equal ratios, each at a 5% dilution from stock (for detailed protocol see Pereira 
et al., 2019).
Immunohistochemistry
Brain sections were rinsed three times in potassium phosphate buffered saline (KPBS) and pre-
incubated in blocking solution (5% serum and 0.25% TritonX-100 in KPBS) (TKPBS) for 1 hour at 
room temperature. Primary antibodies were then diluted as described in Table 4 in the same pre-incu-
bation solution, added to sections and left over-night at 4°C. The primary antibody was removed and 
sections were rinsed twice with TKPBS followed by pre-incubation in 5% serum-TKPBS solution 
for 30 minutes at room temperature. Details on the antibody used can be found in Table 4. Sections 
were then incubated in secondary antibodies (Jackson Laboratories, Life Technology) conjugated with 
cy2/488, cy3/555 and cy5/647 for 2 hours at room temperature. Sections were then rinsed 3 times in 
KPBS, mounted on glass slides and coverslipped using glycerol or xylen based media. 
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Table 4 Details of antibodies used in Paper III.
Antibody Host Dilution Provider 
MAP2 Mouse 1:500 Sigma 
NeuN Mouse 1:100 Millipore 
hGFAP Rabbit 1:1000 DAKO 
hNCAM Mouse 1:1000 SanatCRuz 
HuNu Mouse 1:200 Millipore 
GFP Chicken 1:1000 Abcam 
GFP Rabbit 1:5000 Millipore 
TH Rabbit 1:1000 Millipore 
Parvalbumin Mouse 1:2000 Sigma 
ChAT Goat 1:200 Chemicon 
NPY Rabbit 1:5000 Immunostar 
DARPP32 Rabbit 1:1000 Abcam 
GAD65/67 Rabbit 1:1000 Abcam 
vGlut1 Rabbit 1:1000 Synapitc Systems 
Tbr1 Rabbit 1:300 Abcam 
CTIP2 Rat 1:1000 Abcam 
Calretinin Rabbit 1:200 Abcam 
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3D structures and Organoids
Human Fetal Dissection and 3D culture
Human fetal tissues were collected from WPC 6–11.5 old legally terminated embryos at Malmö 
Hospital (Malmö, Sweden) and Addenbrooke’s Hospital (Cambridge, U.K.). Ethical approval for the 
use of  postmortem human fetal tissue was provided by the the Swedish national board of  health 
and welfare in accordance with existing guidelines including informed consent from women seeking 
abortions and by the National Research Ethics Service Committee East of  England - Cambridge 
Central (Local Research Ethics Committee, reference no. 96/085). Samples from U.K. were shipped 
overnight on ice in HIBERNATE media (Thermo Fisher Scientific) to Sweden. Tissue from both 
Sweden and U.K. was dissected in HIBERNATE media. Narrow subdissection of  human VM were 
performed and tissue was later washed in phosphate buffered saline (PBS solution). After 3 washes, 
the tissue was treated with accutase (PAA Laboratories) for 20 min at 37°C degrees. After incubation, 
single cell suspensions were generated by mechanical dissociation and the cells plated at a density of  
70,000 cells/well (36,842 cells/cm2) in culture media (Figure 15). Culture media used was formulated 
as follow: Neurobasal Medium, 2 nM L-Glutamine, 100 µg/mL pen/strep, 20 ng/ml BDNF, 10 ng/
ml GDNF, 0.2 mM AA, 1/3 B27 (Figure 15). Only on plating day after dissociation, the culture media 
was supplemented with Y-27632 (10 µM) for improving neuronal survival. 1% minimum essential 
medium-non essential amino acids (MEM-NEAA) and 0.1% 2-mercaptoethanol was added to the 
culture media from day 14. Media changes were performed every 2 days. 2D cultures were performed 
Figure 15 Overview of fetal hVM 3D cultures procedures.
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in standard plates coated with a combination of  Polyornithine (15 µg/mL), Fibronectin (0.5 ng/µL) 
and Laminin (5 µg/mL). 3D cultures were performed using U-bottom shaped ultra-low attachment 
96-well plates (Corning). Droplets of  Matrigel were applied as embadding at day 30 to sustain long 
term cultures. At the time of  embedding, 3D hVM cultures were transferred into ultra-low attach-
ment 24-well plates (Corning).
3D cultured organoids used for calcium imaging were left attaching on glass coverslips coated 
with Polyornithine, Fibronectin and Laminin at day 90.
VM Organoids Culture
To start 3D VM organoid differentiation, RC17, H9, HS999, HS1001, and TH-Cre hPSC cells 
were detached from the culture dish with 0.5 mM accutase (Thermo Fisher Scientific, #A1110501) 
to yield a single cell suspension. Differentiation was initiated by plating 2,500 single cells in each well 
of  a 96-well U-bottom plate (Corning, #CLS7007) in iPS Brew with 10 µM Y-27632 dihydrochloride 
(Miltenyi, #130-106-538), as previously described (Quadrato et al., 2017; Renner et al., 2017). After 
three days in culture, embryoid bodies were transferred to differentiation medium consisting of  1:1 
DMEM/F12:Neurobasal medium (Thermo Fisher Scientific, #21331020 and #A1371201), 1:100 N2 
supplement (Thermo Fisher Scientific, #A1370701), 10 µM SB431542 (Miltenyi, #130-106-543), 150 
ng/ml rhNoggin (Miltenyi, #130-103-456), 400 ng/ml SHH-C24II (Miltenyi, #130-095-727), and 
1.5 µM CHIR99021 (Miltenyi, #130-106-539), with 200 mM L-glutamine (Thermo Fisher Scien-
tific, #25030081) and 10,000 U/mL penicillin-streptomycin (Thermo Fisher Scientific, #15140122). 
During the whole differentiation period 1% minimum essential medium-non essential amino acids 
(MEM-NEAA; Sigma-Aldrich, #M7145) and 0.1% 2-mercaptoethanol (Merck, #8057400005) were 
maintained. On day 11, developing VM organoids were transferred to a 24-well plate containing 1:50 
Neurobasal medium, B27 supplement without vitamin A (Thermo Fisher Scientific, #12587010), and 
100 ng/mL FGF-8b (Miltenyi, #130-095-740). On day 14, 20 ng/mL BDNF (Miltenyi, #130-096-
286) and 200 mM L-Ascorbic acid (Sigma-Aldrich, #A4403-100MG) were added. At this point, VM 
organoids were embedded in 30 µL droplets of  Matrigel (BD Biosciences), as previously described 
(Lancaster et al., 2014). From day 16 onwards, 0.5 mM db-cAMP (Sigma-Aldrich, #D0627-1G) and 
1 µM DAPT (R&D Systems, #2634) were added to the culture medium for terminal maturation for 
up to four months. 
scRNA-seq
For 10x Genomics single cell RNA sequencing, single cell suspensions were loaded onto 10x 
Genomics Single Cell 3’ Chips along with the mastermix as per the manufacturer’s protocol (https://
support.10xgenomics.com/single-cell-gene-expression/index/doc/technical-note-chromium-single-
cell-3-v3-reagent-workflow-and-software-updates) for the Chromium Single Cell 3’ Library to gener-
ate single cell gel beads in emulsion (GEMs, version 3 chemistry). Resulting libraries were sequenced 
on either a NextSeq500 or a NovaSeq 6000 with the following specifications Read1 28 cycles, Read2 
98 cycles, Index1 8 cycles using a 200 cycle kit. Raw base calls were demultiplexed and converted 
fastq files using cellranger mkfastq program (bcl2fastq 2.19/cellranger 3.0). Sequencing data was first 
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pre-processed through the Cell Ranger pipeline (10x Genomics, Cellranger count v2) with default 
parameters (expect-cells set to number of  cells added to 10x system), aligned to GrCH38 (v 3.1.0) and 
resulting matrix files were used for subsequent bioinformatic analysis. 
Whole-cell patch-clamp recordings
Whole-cell patch-clamp electrophysiological recordings were performed on glass coverslips for 
Paper I-II, on whole 3D cultures of  fetal VM in Paper IV and on sliced VM organoids for Paper V. 
Cell on glass coverslips were with constant flow of  Krebs solution gassed with 95% O2 - 5% CO2 at 
room temperature in the recording chamber. 3D structures and sliced VM organoids were transferred 
to a recording chamber with Krebs solution gassed with 95% O2 - 5% CO2 at room temperature 
without constant flow rather the Krebs solution was exchanged manually at the end of  the recording 
of  each cell. The composition of  the Krebs solution was (in mM): 119 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 
CaCl2, 25 Glucose and 26 NaHCO3. For recordings Multiclamp 700B amplifier (Molecular Devices) 
was used together with borosilicate glass pipettes (5–7 MW) filled with the following intracellular solu-
tion (in mM): 122.5 potassium gluconate, 12.5 KCl, 0.2 EGTA, 10 Hepes, 2 MgATP, 0.3 Na3GTP and 
8 NaCl adjusted to pH 7.3 with KOH. Data acquisition was performed with pClamp 10.2 (Molecular 
Devices); current was filtered at 0.1 kHz and digitized at 2kHz. Cells with neuronal morphology and 
round cell body were selected for recordings. Resting membrane potentials were monitored imme-
diately after breaking-in in current-clamp mode. Thereafter, cells were kept at a membrane potential 
of  -45 mV to -70mV. For detailed Voltage and Current protocol, please refer to methods sections of  
each papers (see appendix).
Figure 16 Representative image of Patch-Seq procedure. 
The cell of interest is targeted by a patch recording pipette and aspirated from the culture. Collected cell is further pro-
cessed for scRNA-seq.
A
B
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Patch Sequencing
Patch-Seq procedure was established similarly to (Bardy et al., 2016). Following electrophysio-
logical recording, slight additional negative pressure was applied (Figure 16). The neuron was then 
transferred in a volume of  ~2 µl of  internal patch solution into a PCR tube by slowly retracting the 
patch pipette from the chamber bath and breaking the tip of  the electrode along the inside wall of  
the tube. Cells were immediately frozen placing the tube on dry ice. For scRNA-seq procedure, cells 
of  interest were thawed at 4°C. Sample buffer was added to the cell and internal solution to reach 
a total volume of  10 ml following instructions supplied by Clontech with the SMARTer Ultra Low 
RNA Kit . Successful removal of  the cell from the 3D fetal culture was always confirmed by DIC 
optics. Collected single cells were processed for SMARTer cDNA synthesis following manufacturer’s 
instructions (Clontech, Mountain View, CA, USA). Briefly, first-strand cDNA was synthesized from 
poly(A)+ RNA by incubation with 1 µl of  3’ SMART CDS Primer II A (24 µM) for 3 min at 72 °C, 
followed by reverse transcription in a 20-µl final reaction volume using 200 units of  SMARTScribe 
Reverse Transcriptase for 90 min at 42 °C and inactivation for 10 min at 70 °C. First-strand cDNA 
was then purified using Agencourt AMPure XP SPRI Beads (Beckman Coulter Genomics, Danvers, 
MA, USA) and amplified by long-distance PCR using the Advantage 2 PCR Kit (Clontech) with the 
following PCR thermocycler program: 95 °C for 1 min, 18 cycles of  95 °C for 15 s, 65 °C for 30 s, 
68 °C for 6 min, and 72 °C for 10 min. PCR-amplified double-stranded (ds) cDNA was immobilized 
onto SPRI beads, purified by two washes in 80% ethanol, and eluted in 12 µl of  purification buffer 
(Clontech). The quality (Agilent 2100 Bioanalyzer High Sensitivity DNA Kit; Agilent Technologies, 
Santa Clara, CA, USA) and quantity (Qubit dsDNA High Sensitivity Assay Kit; Invitrogen/Thermo 
Fisher Scientific) of  each ds cDNA sample were assessed before library preparation. Construction of  
single-cell mRNA-seq libraries was performed using the Nextera XT DNA sample prep kit (Illumina) 
with 0.25 ng of  input cDNA. 
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